PH12018502445A1 - Compositions and methods for treating negative symptoms in non-schizophrenic patients - Google Patents
Compositions and methods for treating negative symptoms in non-schizophrenic patientsInfo
- Publication number
- PH12018502445A1 PH12018502445A1 PH12018502445A PH12018502445A PH12018502445A1 PH 12018502445 A1 PH12018502445 A1 PH 12018502445A1 PH 12018502445 A PH12018502445 A PH 12018502445A PH 12018502445 A PH12018502445 A PH 12018502445A PH 12018502445 A1 PH12018502445 A1 PH 12018502445A1
- Authority
- PH
- Philippines
- Prior art keywords
- compositions
- methods
- negative symptoms
- schizophrenic patients
- treating negative
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000024891 symptom Diseases 0.000 title abstract 2
- 230000000698 schizophrenic effect Effects 0.000 title 1
- 238000003759 clinical diagnosis Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341590P | 2016-05-25 | 2016-05-25 | |
| PCT/US2017/034030 WO2017205393A1 (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12018502445A1 true PH12018502445A1 (en) | 2019-09-09 |
Family
ID=58794265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12018502445A PH12018502445A1 (en) | 2016-05-25 | 2018-11-20 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190216793A1 (enExample) |
| EP (1) | EP3463356A1 (enExample) |
| JP (3) | JP2019516756A (enExample) |
| KR (2) | KR20240005110A (enExample) |
| CN (3) | CN113908156A (enExample) |
| PH (1) | PH12018502445A1 (enExample) |
| SG (2) | SG10202011470UA (enExample) |
| TW (2) | TWI820001B (enExample) |
| WO (1) | WO2017205393A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015355226B2 (en) | 2014-12-02 | 2020-04-02 | Minerva Neurosciences, Inc. | Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
| US11083723B2 (en) * | 2018-08-21 | 2021-08-10 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| TWI879755B (zh) * | 2020-02-20 | 2025-04-11 | 日商田邊三菱製藥股份有限公司 | 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途 |
| KR102360137B1 (ko) * | 2020-03-25 | 2022-02-08 | 주식회사 케이티앤지 | 카트리지 및 이를 포함하는 에어로졸 생성 장치 |
| CN116847843A (zh) * | 2021-02-09 | 2023-10-03 | 泽农医药公司 | 用于治疗快感缺乏的电压门控的钾通道开放剂 |
| US20240212824A1 (en) * | 2022-12-21 | 2024-06-27 | Woebot Labs, Inc. | Administering a digital therapeutic using a device interface to treat anxiety or depression |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ521576A (en) * | 2000-02-29 | 2005-06-24 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
| TW200616608A (en) * | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| EP1986647A4 (en) * | 2006-02-07 | 2009-09-02 | Mitsubishi Tanabe Pharma Corp | BY NEUROGENESIS MEDIATED BY 4-ACYLAMINOPYRIDINE DERIVATIVES |
| JP2008273954A (ja) * | 2007-03-30 | 2008-11-13 | Mitsubishi Tanabe Pharma Corp | うつ病の予防及び／又は治療剤 |
| SI3135286T1 (sl) * | 2010-07-20 | 2024-02-29 | Minerva Neurosciences, Inc. | Postopek uporabe derivatov cikličnega amida za zdravljenje shizofrenije in njenih simptomov |
| RU2746871C2 (ru) * | 2010-07-20 | 2021-04-21 | Сиренейк Фармасьютикалз Инк. | Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств |
| US8937900B2 (en) * | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| JP6531093B2 (ja) * | 2014-05-16 | 2019-06-12 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| AU2015355226B2 (en) * | 2014-12-02 | 2020-04-02 | Minerva Neurosciences, Inc. | Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
-
2017
- 2017-05-23 EP EP17726525.3A patent/EP3463356A1/en not_active Withdrawn
- 2017-05-23 KR KR1020237043697A patent/KR20240005110A/ko not_active Ceased
- 2017-05-23 JP JP2018561528A patent/JP2019516756A/ja active Pending
- 2017-05-23 SG SG10202011470UA patent/SG10202011470UA/en unknown
- 2017-05-23 CN CN202111014298.8A patent/CN113908156A/zh active Pending
- 2017-05-23 CN CN201780045461.2A patent/CN109689055A/zh active Pending
- 2017-05-23 US US16/302,722 patent/US20190216793A1/en not_active Abandoned
- 2017-05-23 KR KR1020187036656A patent/KR20190013846A/ko not_active Ceased
- 2017-05-23 SG SG11201810358YA patent/SG11201810358YA/en unknown
- 2017-05-23 WO PCT/US2017/034030 patent/WO2017205393A1/en not_active Ceased
- 2017-05-23 CN CN202111014262.XA patent/CN113694065A/zh active Pending
- 2017-05-23 TW TW106117023A patent/TWI820001B/zh active
- 2017-05-23 TW TW112118953A patent/TWI851224B/zh active
-
2018
- 2018-11-20 PH PH12018502445A patent/PH12018502445A1/en unknown
-
2022
- 2022-05-26 US US17/825,783 patent/US20230190726A1/en not_active Abandoned
- 2022-10-04 JP JP2022160201A patent/JP2022188185A/ja active Pending
-
2024
- 2024-10-02 JP JP2024173054A patent/JP2025000921A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025000921A (ja) | 2025-01-07 |
| JP2022188185A (ja) | 2022-12-20 |
| JP2019516756A (ja) | 2019-06-20 |
| TW201808288A (zh) | 2018-03-16 |
| US20230190726A1 (en) | 2023-06-22 |
| CN113694065A (zh) | 2021-11-26 |
| SG10202011470UA (en) | 2021-01-28 |
| CN109689055A (zh) | 2019-04-26 |
| KR20190013846A (ko) | 2019-02-11 |
| KR20240005110A (ko) | 2024-01-11 |
| TWI851224B (zh) | 2024-08-01 |
| TW202335672A (zh) | 2023-09-16 |
| WO2017205393A1 (en) | 2017-11-30 |
| EP3463356A1 (en) | 2019-04-10 |
| TWI820001B (zh) | 2023-11-01 |
| US20190216793A1 (en) | 2019-07-18 |
| CN113908156A (zh) | 2022-01-11 |
| SG11201810358YA (en) | 2018-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502445A1 (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| ZA201606320B (en) | Human plasma kallikrein inhibitors | |
| PH12016502582A1 (en) | TrK-INHIBITING COMPOUND | |
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| TN2015000505A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
| EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| MY199027A (en) | Method for treating or preventing ophthalmological conditions | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| PH12018500678A1 (en) | Human plasma kallikrein inhibitors | |
| ZA202409847B (en) | Gastro-resistant controlled release oral dosage forms | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| PH12015501793B1 (en) | Bicyclic compounds | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX380301B (es) | Prevención o tratamiento de enfermedades urinarias o gotosas. | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| MX2020009334A (es) | Compuestos para tratar la enfermedad de alzheimer. | |
| NZ799881A (en) | Gastro-resistant controlled release oral dosage forms | |
| HK1245077A1 (en) | Compositions and methods of treating a neurodegenerative disease | |
| TH158821A (th) | วิธีการของการใช้งานของสารประกอบฟีนอกซีโพรพิลเอมีน เพื่อบำบัดภาวะซึมเศร้า | |
| BR112017005050A2 (pt) | composição farmacêutica, nebulizador e método de tratamento ou prevenção de doenças | |
| HK1236052A1 (en) | Compounds for use as imaging agents |